Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients.
Zhiwu TanMei Sum ChiuXinxiang YangMing YueTan To CheungDongyan ZhouYuewen WangAnthony Wing-Hung ChanChi Wing YanKa Yi KwanYik Chun WongXin LiJingying ZhouKa Fai ToJiye ZhuChung Mau LoAlfred Sze-Lok ChengStephen Lam ChanLi LiuYou-Qiang SongKwan ManZhiwei ChenPublished in: Gut (2022)
Our findings not only revealed a mechanism underlying resistance to PD-1 ICB but also identified anti-Δ42PD-1 antibody for HCC immunotherapy.